Novavax COVID-Flu Vaccine Shows Strong Immune Response in Trial
June 11, 2025: Novavax’s experimental COVID-19-influenza combination vaccine and standalone flu vaccine demonstrated a strong immune response in adults aged 65 and older, according to a late-stage trial involving 2,000 participants.
The Maryland-based biotech confirmed that both vaccines were well-tolerated with no new safety concerns. The combination vaccine was tested against Nuvaxovid, Novavax’s COVID-19 shot, and Fluzone HD, Sanofi’s flu vaccine.
Although the study was not designed to yield statistically significant results, the data will support a future late-stage trial aimed at securing regulatory approval.
Novavax, which is focusing on commercial partnerships, continues to seek collaborators for advancing its vaccine candidates. Last year, it signed a $1.2 billion licensing deal with Sanofi to further develop Nuvaxovid, which recently received FDA approval for use in older adults and at-risk individuals over 12.
The protein-based vaccine offers an alternative to mRNA-based options, such as those from Pfizer and Moderna, strengthening Novavax’s foothold in the vaccine market.
You May Interested In
2026-09-06
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
South Korea Approves Yeosu Restructuring Plan, Permanently Retiring 1.39 Million Tons of Ethylene Capacity
-
European Petrochemicals Enter 'Era of Downsizing' as Dow, TotalEnergies, Shell Exit Older Cracker Assets
-
$530 Million Lawsuit Unheard, $76 Million Counterclaim Filed: Is Qicai Chemical’s ‘Reputation Defense’ a Desperate Last Stand or a Calculated PR Gambit?
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
Rhine Drought Disrupts German Chemical Logistics, Raising Supply Risks for BASF, Covestro and Evonik
-
Global Oil Inventories Fall: Restocking Demand May Keep Petrochemical Costs Supported
-
Sun Pharma’s Secret Sauce: Solve the Specific, Win the Market
-
China’s PE, PP and PVC Exports Rise as Stockpile Releases Reshape Global Supply
-
The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
-
China Suspends Sulfuric Acid Exports, Global Copper and Fertilizer Supply Under Strain
Recommend Reading
-
![Uzbekistan Bets $17 Billion on Chemical Industry Upgrade]()
Uzbekistan Bets $17 Billion on Chemical Industry Upgrade
-
![He Spent 40 Years at Nestlé—Then Was “Cleared Out” Days After Becoming CEO: This Isn’t a Scandal, It’s Capital’s Coldest Face]()
He Spent 40 Years at Nestlé—Then Was “Cleared Out” Days After Becoming CEO: This Isn’t a Scandal, It’s Capital’s Coldest Face
-
![Global Biologicals M&A Storm: How 2025 Redrew the Agricultural Innovation Map]()
Global Biologicals M&A Storm: How 2025 Redrew the Agricultural Innovation Map
-
![Australia Launches Anti-Circumvention Trade Probe into China’s 2,4-D Supply Chain]()
Australia Launches Anti-Circumvention Trade Probe into China’s 2,4-D Supply Chain
-
![Sun Pharma’s Utreglutide Shows Promising Weight Loss and Liver Fat Reduction]()
Sun Pharma’s Utreglutide Shows Promising Weight Loss and Liver Fat Reduction
-
![Premium Global Chemical Sourcing Requests (20-23Aug, 2026)]()
Premium Global Chemical Sourcing Requests (20-23Aug, 2026)
-
![Formic Acid Shows a Stepped Downward Trend in Early June]()
Formic Acid Shows a Stepped Downward Trend in Early June
-
![Moving Average Crossover, June Isooctanol Prices in China Rise]()
Moving Average Crossover, June Isooctanol Prices in China Rise
-
![Supply Pressure Doubles, Hydrogen Peroxide Prices Continue to Fall in China]()
Supply Pressure Doubles, Hydrogen Peroxide Prices Continue to Fall in China
-
![Premium Global Chemical Sourcing Requests (4-8 Oct 2025)]()
Premium Global Chemical Sourcing Requests (4-8 Oct 2025)
